ClinicalTrials.gg
CompletedNCT00072839Updated May 25, 2021

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

A Phase 2 interventional study of ALX-0600 and placebo in Crohn's Disease, sponsored by Shire. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.

Enrollment
26th of 51
100 · median 100
Started
2003
the only one that year
Phase 2
13 of 86
3 open now
Registered
1st of 86
by date

Among the 86 studies in Crohn Disease by Takeda, this one is the 26th largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2003, is one of 13 in phase 2, and was the 1st registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Crohn Disease by Takeda, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.

Read the detailed description

The study is twelve weeks in duration and there are eight weeks of once-daily injections into your abdomen or thigh. There are a total of six visits.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women, 18 years of age and older
  2. Signed and dated to participate before any study-related procedures are performed
  3. Diagnosis of Crohn's disease for at least 6 months that has been documented and confirmed
  4. A Crohn's Disease Activity Index (CDAI) score of 220 to 450 inclusive
  5. Female subjects who are not surgically sterile or must use medically acceptable methods of during and for 30 days after the treatment period.
  6. HCT 30% or greater
  7. WBC 3.5 x 109/L or greater
  8. 100 x 109/L or greater
  9. Adequate renal function defined as: serum creatinine and BUN 1.5 x or less
  10. Adequate hepatic function defined as: /SPGT, AST/SGOT 2.0 x ULN or less; total 1.25 x ULN or less, alkaline phosphatase 1.5 x ULN or less
  11. Female subjects of must have negative urine pregnancy test results prior to randomization
  12. A stool sample must be taken at screening and analyzed by a local laboratory for enteric pathogens, pathogenic ova and parasites, and Clostridium difficile toxin, and reported negative prior to randomization.
  13. C-reactive protein value must be 1.0 mg/dL or more, unless there are obvious manifestations of currently active Crohn's disease such as positive observations on endoscopy, other positive indications by laboratory test results, or the subject has had a previous intestinal resection for Crohn's disease.

Exclusion criteria

Exclusion Criteria

  1. Nutritionally compromised subjects requiring enteral or parenteral therapy to maintain weight
  2. Body weight less than 40 kg or more than 100 kg
  3. Bowel obstruction or any condition that may predispose to its development, intestinal perforation, or significant gastrointestinal hemorrhage
  4. Current ileostomy or colostomy or extensive external fistulization (more than 3 external fistulae which are expressible with gentle compression)
  5. Expected to require surgical therapy for Crohn's disease or Crohn's disease related complications within 12 weeks of screening. If an abscess is present, it should be drained at least 3 weeks before pre-screening
  6. History of ulcerative colitis within 6 months of screening visit
  7. Cushing's syndrome
  8. Known infection, or symptoms or signs of HIV infection
  9. Acute systemic infection and/or intestinal infection requiring antibiotic therapy at time of screening or baseline
  10. Evidence of chronic or C viral infection
  11. Decompensated liver disease
  12. abnormalities
  13. History of angina or cardiac arrhythmia requiring drug or device intervention or clinically significant congestive heart failure or other clinically significant cardiac disease
  14. History of myocardial infarction within 12 months of screening
  15. History of thromboembolic disease (e.g., phlebitis, pulmonary embolus) or known congenitally or acquired prothrombotic disorder (e.g., protein C deficiency)
  16. History of cancer (other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer) or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state
  17. Known substance abuse in the previous 2 years
  18. Nursing mothers or pregnant women
  19. Use of native GLP-2, growth hormone, or growth factors within 3 months of signing
  20. Use of any of the prior or concomitant medications described in section 5.4, except as specified
  21. Known to any of the active or inactive constituents of ALX-0600
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    placebo solution injected subcutaneously daily into either thigh or abdomen.

    Drug: placebo

  • Experimental
    teduglutide 0.05

    teduglutide 0.05 mg/kg/d injected subcutaneously daily.

    Drug: Teduglutide 0.05 dose

  • Experimental
    teduglutide 0.1

    0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen

    Drug: teduglutide 0.1 mg dose

  • Experimental
    teduglutide

    0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen

    Drug: ALX-0600 · Drug: teduglutide 0.05 · Drug: teduglutide 0.2 mg

Interventions

  • teduglutide

    Also known as: GATTEX

  • Drugplacebo

    placebo solution injected subcutaneously

  • 0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen

    Also known as: GATTEX

  • 0.2 mg/kg/d subcutaneously injected into thigh or abdomen

    Also known as: GATTEX

  • 0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen

    Also known as: GATTEX

  • 0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen

    Also known as: GATTEX

06

What researchers measure

Primary outcomes

  1. The primary efficacy variable is the percentage of subjects who respond to treatment, defined as the percentage of subjects who are in remission (CDAI less than 150) or have a 100-point or greater reduction from baseline in CDAI score at dosing Week 8.

    Time frame: 8 weeks of treatment

Secondary outcomes

  1. The various secondary efficacy variables are based on the CDAI, Inflammatory Bowel Disease Questionnaire (IBDQ), plasma citrulline and laboratory inflammatory markers.

    Time frame: 8 weeks of treatment

07

Study locations

26 sites
  • Advanced Clinical Therapeutics
    Tucson, Arizona 85712, United States
  • Rocky Mountain Gastroenterology
    Lakewood, Colorado 80401, United States
  • Rx Trials
    Washington, District of Columbia 20010, United States
  • Clinical Trials Management of Boca Raton
    Boca Raton, Florida 33486, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Venture Research
    North Miami Beach, Florida 33162, United States
  • Visions Clinical Research - Sarasota
    Sarasota, Florida 34239, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Pinnacle Trials
    Atlanta, Georgia 30329, United States
  • Saint Joseph's Health System
    Atlanta, Georgia 30342-1764, United States
  • Northwestern University School of Medicine
    Chicago, Illinois 60619, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Asher Kornbluth, MD, PC
    New York, New York 10128, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Allegheny General Hospital-Allegheny Ctr for Digestive Diseases
    Pittsburgh, Pennsylvania 15212, United States
  • Methodist Hospital/Baylor University
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • Dean Foundation Research Center
    Madison, Wisconsin 53715, United States
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1L5, Canada
  • Odyssey Research
    Victoria, British Columbia V8T 5G4, Canada
  • Health Sciences Center
    Winnipeg, Manitoba R3A 1R9, Canada
  • Queen Elizabeth II Health Sciences
    Halifax, Nova Scotia B3H 1V7, Canada
  • Life Screening Centres
    Toronto, Ontario M5S 2A5, Canada
08

References and documents

Publications

  • Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis. 2010 Jun;16(6):962-73. doi: 10.1002/ibd.21117. PubMed 19821509 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2003 to primary completion in Jul 2005, 20 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 20 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2003
First posted
Nov 13, 2003
StartActual
Nov 12, 2003
Primary completionActual
Jul 28, 2005
CompletionActual
Jul 28, 2005
Last update
May 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00072839
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 13, 2003
Start date
Nov 12, 2003
Primary completion
Jul 28, 2005
Completion
Jul 28, 2005
Last update
May 25, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion